Financial Summary for the First Quarter of the Fiscal Year Ending October 2026 [Japanese GAAP] (Consolidated)

Overview of Financial Performance

In the first quarter of the fiscal year ending October 2026, net sales increased to 9,404 million yen (3.9% increase YoY), while operating income declined to 1,519 million yen (16.1% decrease YoY), ordinary income to 1,538 million yen (15.5% decrease YoY), and quarterly net income attributable to owners of parent decreased to 894 million yen (29.0% decrease YoY). The main factors behind the decline in profits were an increase in hardware sales composition due to overlapping operations of relatively large medical institutions, external environmental impacts such as semiconductor material supply-demand constraints, and the posting of a special loss of 240 million yen related to the reconstruction of employee dormitories. The company operates in a single segment of medical information systems, and additional demand for DX-related systems remains steady.

Financial Position and Outlook

Total assets were 51,179 million yen, down 1,009 million yen from the end of the previous fiscal year, while net assets increased by 67 million yen to 41,963 million yen. Liabilities stood at 9,215 million yen, showing a decreasing trend. There is no change to the dividend forecast, with an annual dividend of 170 yen planned. The full-year consolidated earnings forecast remains unchanged, anticipating net sales of 44,338 million yen (4.8% increase YoY), operating income of 8,795 million yen (4.8% increase YoY), and net income attributable to owners of parent of 5,982 million yen (2.1% decrease YoY). Although economic uncertainty remains, the company will leverage tailwinds from the promotion of medical and nursing care DX to build a foundation for sustainable growth.